优化EGPA的激素依赖与复发管理
填补HES长期控制的治疗缺口
拓展儿童SEA的生物制剂选择
参考文献:
[1] 国家医疗保障局, 人力资源和社会保障部. 国家基本医疗保险、工伤保险和生育保险药品目录(2026年)[Z]. 2026.
[2] 本瑞利珠单抗注射液说明书(30 mg自动注射笔).
[3] Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthma with sputum eosinophilia. J Allergy Clin Immunol, 2013, 132(5): 1086-1096.e5.
[4] 林慧敏, 符昱, 方章福, 等. 嗜酸性粒细胞哮喘的研究进展. 结核与肺部疾病杂志, 2022, 3(4): 328-333.
[5] Global Initiative for Asthma. Global strategy for asthma management and prevention: 2026 update. 2026.
[6] 中华医学会儿科学分会呼吸学组, 等. 儿童支气管哮喘诊断与防治指南(2025年). 中华儿科杂志, 2025, 63(4): 324-337.
[7] Jakes RW, Kwon N, Nordstrom B, et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol, 2021, 40(12): 4829-4836.
[8] Wechsler ME, Nair P, Terrier B, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med, 2024, 390(10): 911-921.
[9] Merkel PA, Nair PK, Khalidi N, et al. Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis, 2025, 84(11): 1888-1899.
[10] Hypereosinophilic syndrome. National Organization for Rare Disorders (NORD) Rare Disease Database. https://rarediseases.org/rare-diseases/hypereosinophilic-syndrome/
[11] Hwee J, Huynh L, Du S, et al. Hypereosinophilic syndrome in Europe: retrospective study of treatment patterns, clinical manifestations, and healthcare resource utilization. Ann Allergy Asthma Immunol, 2023, 130(6): 768-775.
[12] Kuang FL, Khoury P, Weller PF, et al. Biologics and hypereosinophilic syndromes: knowledge gaps and controversies. J Allergy Clin Immunol Pract, 2023, 11(9): 2666-2671.
[13] Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol, 2020, 146(6): 1398-1406.
[14] Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med, 2026, 32(6): 2017-2025.
[15] Gouia I, Joulain F, Zhang Y, et al. Clinical burden and healthcare resource use of asthma in children in the UK. J Asthma Allergy, 2025, 18: 161-171.
[16] Tai A, Tran H, Roberts M, et al. The association between childhood asthma and adult chronic obstructive pulmonary disease. Thorax, 2014, 69(9): 805-810.
[17] Wedner HJ, Fujisawa T, Guilbert TW, et al. Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study). Pediatr Allergy Immunol, 2024, 35(3): e14092.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
文章原文
